TORONTO, Canada – Biogen Canada Inc. is encouraged by the recent Health Technology Assessment (HTA) evaluations issued by Canada’s Drug Agency (CDA) and the Institut national d’excellence en santé et en services sociaux (INESSS) for QALSODY™ (tofersen injection), the first therapy designed to target a known genetic cause of amyotrophic lateral sclerosis (ALS).   CDA Issues Positive Reimbursement...

PARIS, France – The National Medical Products Administration (NMPA) in China has approved two innovative Sanofi medicines for rare hematologic diseases: Qfitlia (fitusiran) for hemophilia and Cablivi (caplacizumab) for acquired thrombotic thrombocytopenic purpura. These approvals mark another step in Sanofi’s long-term commitment to China, reinforcing the company’s ambition to bring...

SAN DIEGO, Calif. — Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, announced that the first patient has been dosed in Australia in its Phase 3 HERO pivotal clinical trial assessing...